References
- Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother. 2011;66(Suppl 4):iv43–8.
- Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother. 2009;64(Suppl 1):i29–36.
- Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, Hazzan R, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65:2658–65.
- Bazan JA, Martin SI. Ceftaroline fosamil: a novel broad-spectrum cephalosporin. Drugs Today (Barc). 2010;46:743–55.
- Flamm RK, Sader HS, Farrell DJ, Jones RN. Summary of ceftaroline activity against pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob Agents Chemother. 2012;56:2933–40.
- ZinforoTM, 2012. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002252/WC500132586.pdf (accessed 2012 May).
- CLSI. M2-A09. Performance standards for antimicrobial disk susceptibility tests; approved standard, 9th edn. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
- CLSI. M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
- EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, 2013. Available from http://www.eucast.org/clinical_breakpoints/ (accessed 2013 January 2)
- Tygacil®, 2012. Available from: www.tygacil.com (accessed 2013 January).
- Castanheira M, Mendes RE, Woosley LN, Jones RN. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: Report from the SENTRY Antimicrobial Surveillance Programme (2007–09). J Antimicrob Chemother. 2011;66:1409–11.